Advanced models for respiratory disease and drug studies.

Autor: Shrestha J; School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia., Paudel KR; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia., Nazari H; School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia., Dharwal V; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia., Bazaz SR; School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia., Johansen MD; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia., Dua K; Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, New South Wales, Australia.; Faculty of Health, Australian Research Centre in Complementary & Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales, Australia., Hansbro PM; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia., Warkiani ME; School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.; Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Medicinal research reviews [Med Res Rev] 2023 Sep; Vol. 43 (5), pp. 1470-1503. Date of Electronic Publication: 2023 Apr 29.
DOI: 10.1002/med.21956
Abstrakt: The global burden of respiratory diseases is enormous, with many millions of people suffering and dying prematurely every year. The global COVID-19 pandemic witnessed recently, along with increased air pollution and wildfire events, increases the urgency of identifying the most effective therapeutic measures to combat these diseases even further. Despite increasing expenditure and extensive collaborative efforts to identify and develop the most effective and safe treatments, the failure rates of drugs evaluated in human clinical trials are high. To reverse these trends and minimize the cost of drug development, ineffective drug candidates must be eliminated as early as possible by employing new, efficient, and accurate preclinical screening approaches. Animal models have been the mainstay of pulmonary research as they recapitulate the complex physiological processes, Multiorgan interplay, disease phenotypes of disease, and the pharmacokinetic behavior of drugs. Recently, the use of advanced culture technologies such as organoids and lung-on-a-chip models has gained increasing attention because of their potential to reproduce human diseased states and physiology, with clinically relevant responses to drugs and toxins. This review provides an overview of different animal models for studying respiratory diseases and evaluating drugs. We also highlight recent progress in cell culture technologies to advance integrated models and discuss current challenges and present future perspectives.
(© 2023 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: